Fibocom and Aetina Collaborate to Bring 5G Release 16 Capabilities to AI Edge Computer Based on NVIDIA® Jetson Xavier™ NX
Fibocom (Stock Code: 300638), a global leading provider of IoT (Internet of Things) wireless solutions and wireless communication modules, announced the collaboration with Aetina Corporation, the provider of high-performance GPGPU and edge AI computing solutions, during Embedded World 2022. The joint effort aims to bring high-speed, ultra-reliable and low-latency 5G capacities, enabled by Fibocom’s 5G R16-compliant module FM160-EAU, to Aetina’s AN810-XNX AI edge computing platform, empowering robotics, UAV, industrial IoT, smart healthcare and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005419/en/
Fibocom and Aetina Collaborate to Bring 5G Release 16 Capabilities to AI Edge Computer Based on NVIDIA® Jetson Xavier™ NX (Photo: Fibocom)
Combining Artificial Intelligence (AI) and IoT, dubbed AIoT, has opened up new possibilities for an era of smarter, faster decision-making. The rapid reaction time that AIoT offers is the result of shifting computing power to the edge. Based on NVIDIA Jetson Xavier NX, Aetina AN810-XNX is the world's leading platform for high-performance and energy-efficient AI computing. This edge computing platform fully supports M.2 device with extension slot, that assist developers expand their systems communication ability, I/O connectivity flexibly and quickly.
5G allows AIoT to overcome the data-transmission bottleneck, while analyzing and learning from data with rapid precision. Compliant with 3GPP Release16 (R16) standards, Fibocom FM160-EAU is a high-performance 5G M.2 module supporting NR Carrier Aggregation (CA), which optimizes 5G user experience with lightning-fast speed, extended coverage, boosted throughput and increased capacity. Embedded in Aetina AN810-XNX AI edge computing platform, FM160-EAU delivers enhanced 5G R16 capabilities to the edge, allowing businesses and industry benefit from intelligent and autonomous decision-making.
Moving forward, Fibocom and Aetina will deepens relationship, optimizing AI edge computing solutions based on Nvidia Jetson AGX Orin platform with high-performance 5G module featuring latest 3GPP standards. In collaboration with industry partners, Fibocom and Aetina are committed to enhance the development of 5G AIoT.
“Aetina has been building a wide and strong ecosystem network in global edge AI industry,” said Austin Lin, Jetson Series Product Division Head, Aetina. “This partnership with Fibocom benefits our clients with their growing demand of developing reliable AI platforms with real-time connectivity at the edge.”
“Our collaboration with Aetina reflects Fibocom’s commitment to building out the AIoT world,” said Simon Tao, General Manager of MBB Product Management Dept., Fibocom. “By bringing 5G capacities to the edge, AIoT can deliver on the full promise of its potential, ushering in a new era of massive connectivity that will revolutionize how we live, work and play.”
About Aetina
Aetina Corporation, founded in 2012 in Taipei, Taiwan, is a leading provider of high-performance GPGPU and Jetson edge AI computing solutions for embedded applications. With a focus on the industrial market, we provide industrial components and longevity services, and we are also an integrator in the AIoT market, easing customer pain points by offering smart, innovative, and reliable GPU solutions that satisfy their needs.
About Fibocom
Fibocom is a leading global provider of wireless communication modules and solutions in the sector of IoT (Internet of Things), as well as the first stock-listed (Stock Code:300638) wireless module provider in China. We provide end-to-end IoT wireless communication solutions for telecom operators, IoT equipment manufacturers, and IoT system integrators. With over two decades' engagement in M2M and IoT communication technology and extensive expertise, we are capable of independently developing high-performance wireless communication modules including 5G, LTE/LTE-A, NB-IoT/LTE-M, Android Smart, Automotive, WCDMA/HSPA(+), GSM/GPRS, Wi-Fi, GNSS, etc. Besides reliable, convenient, safe and intelligent IoT communication solutions for almost all vertical industries, we are also geared to customize the best and optimal IoT modules and solutions catering to your special requirements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005419/en/
Contact information
Media
Ellie Cai
pr@fibocom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom